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Survival of motor neuron (SMN) deficiency causes spinal muscular atrophy (SMA), but the pathogenesis
mechanisms remain elusive. Restoring SMN in motor neurons only partially rescues SMA in mouse models,
although it is thought to be therapeutically essential. Here, we address the relative importance of SMN restoration
in the central nervous system (CNS) versus peripheral tissues in mouse models using a therapeutic splice-
switching antisense oligonucleotide to restore SMN and a complementary decoy oligonucleotide to neutralize its
effects in the CNS. Increasing SMN exclusively in peripheral tissues completely rescued necrosis in mild SMA
mice and robustly extended survival in severe SMAmice, with significant improvements in vulnerable tissues and
motor function. Our data demonstrate a critical role of peripheral pathology in the mortality of SMA mice and
indicate that peripheral SMN restoration compensates for its deficiency in the CNS and preserves motor neurons.
Thus, SMA is not a cell-autonomous defect of motor neurons in SMA mice.
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Spinal muscular atrophy (SMA) is the leading genetic
cause of pediatric mortality and is characterized by
weakness and paralysis of voluntary muscles due to
spinal cord a-motor neuron degeneration (Crawford and
Pardo 1996). Homozygous loss or mutation of the sur-
vival motor neuron 1 (SMN1) gene is responsible for SMA
(Lefebvre et al. 1995). Humans have a closely related
paralog, SMN2; both genes are ubiquitously expressed
and encode an identical full-length protein. However,
a nucleotide transition (C6T) in SMN2 exon 7 causes
predominant skipping of the exon during pre-mRNA
splicing, resulting in a truncated protein isoform
(SMND7) as the major product, which is rapidly degraded
(Lorson et al. 1999; Monani et al. 1999). SMN2 still
expresses some full-length SMN mRNA and protein,
which is not sufficient to compensate for the lack of
SMN1 but is essential for the survival of SMA patients.
SMN2 is an SMA modifier: Patients or mouse models
carrying one or two copies of SMN2 generally have the
most severe form of SMA (type I), whereas those with
a higher copy number have milder phenotypes (type II, III,
or IV) (McAndrew et al. 1997).
SMN forms a complex with Gemin proteins and acts as
a chaperone to assist the assembly of U snRNPs, essential
components of the spliceosome (Meister et al. 2001).
SMN is also thought to be involved in axonal mRNP
transport inmotor neurons (Rossoll et al. 2003). However,
how suboptimal levels of SMN lead to SMA is largely
unknown. Multiple studies in SMA mouse models
revealed widespread synaptic defects in neuromuscular
junctions (NMJs), including neurofilament accumula-
tion, poor terminal arborization, immature endplates,
reduced quantal content, disturbed calcium homeostasis,
and decreased remodeling potential; these defects precede
motor neuron death (Cifuentes-Diaz et al. 2002; Le et al.
2005; Jablonka et al. 2007; Kariya et al. 2008; Murray
et al. 2008, 2012; Kong et al. 2009; Ling et al. 2010; Ruiz
et al. 2010; Lee et al. 2011), suggesting that the NMJ
alterations are the initial consequence of SMN deficiency,
 2015 Hua et al. This article is distributed exclusively by Cold Spring
Harbor Laboratory Press for the first six months after the full-issue
publication date (see http://genesdev.cshlp.org/site/misc/terms.xhtml).
After six months, it is available under a Creative Commons License
(Attribution-NonCommercial 4.0 International), as described at http://
creativecommons.org/licenses/by-nc/4.0/.
Corresponding authors: krainer@cshl.edu, huay@cshl.edu, ymhua@suda.
edu.cn
Article published online ahead of print. Article and publication date are
online at http://www.genesdev.org/cgi/doi/10.1101/gad.256644.114.
288 GENES & DEVELOPMENT 29:288–297 Published by Cold Spring Harbor Laboratory Press; ISSN 0890-9369/15; www.genesdev.org
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
which then results in motor neuron death and muscle
atrophy.
Recently, Ling et al. (2012) systematically examined
NMJs in a severe mouse model (SMND7) and found that
several muscles are selectively denervated to varying
degrees due to failure in synapse maintenance rather
than initial synapse formation. Sensory motor synaptic
defects in the spinal cord have also been observed (Ling
et al. 2010; Park et al. 2010; Mentis et al. 2011). Three
recent studies demonstrated that both peripheral and
central synaptic defects are autonomously caused by
insufficient levels of SMN in motor neurons (Gogliotti
et al. 2012; Lee et al. 2012; Martinez et al. 2012).
However, increasing SMN levels in motor neurons,
although sufficient to restore both NMJ and sensory
motor synaptic integrity, only partially ameliorates the
phenotype of SMA mice, including a limited increase in
survival (Gogliotti et al. 2012; Lee et al. 2012; Martinez
et al. 2012). These data suggest that defects in tissues
other than motor neurons contribute substantially to the
rapid mortality of mice with severe SMA.
SMA patients and mouse models exhibit widespread
abnormalities in various cell types, tissues, and organs,
aside from spinal cord motor neurons (Hamilton and
Gillingwater 2013). In the central nervous system
(CNS), impaired neuritogenesis and neurogenesis in the
hippocampus and retina have been observed (Wishart
et al. 2010; Liu et al. 2011). In the peripheral nervous
system (PNS), loss of Schwann cells and sensory neurop-
athy have been documented (Rudnik-Schoneborn et al.
2003; Murray et al. 2012; Yonekawa et al. 2013). Muscle
atrophy is one of the two hallmarks of SMA. However,
although there is a reduction in muscle fiber number and
size (due to compromised muscle growth, lack of myo-
fiber maturation, and premature differentiation of satel-
lite cells), the importance of muscle SMN levels in SMA
pathology is controversial (Braun et al. 1995; Gavrilina
et al. 2008; Lee et al. 2011; Hayhurst et al. 2012). Martinez
et al. (2012) recently demonstrated that increased SMN in
muscle—including myoblasts and satellite cells, two cell
types critical for muscle growth and maintenance—
slightly extends the survival of SMA mice, supporting
the conclusion that the deficiency of SMN in muscles
also contributes to the mortality of SMA mice.
Distal necrosis is a phenotypic feature in both mild and
severe SMA mouse models (Hsieh-Li et al. 2000; Tsai
et al. 2006; Narver et al. 2008); digital necrosis has also
been observed, albeit infrequently, in infants with severe
SMA (Araujo et al. 2009; Rudnik-Schoneborn et al. 2010).
Furthermore, cardiac failure is a common phenotypic
trait in severe mouse models and has also been reported
in some severe SMA patients (Rudnik-Schoneborn et al.
2008; Bevan et al. 2010; Heier et al. 2010; Shababi et al.
2010). In addition, bone defects were reported in both
SMA patients and mouse models (Shanmugarajan et al.
2007, 2009). More recently, Bowerman et al. (2012) un-
covered abnormal expansion of a cells and shrinkage of b
cells in the pancreatic islets of SMA mice, resulting in
hyperglucagonemia and defective glucose metabolism. In
spite of these global peripheral defects seen in both
patients and animal models, their importance in SMA
pathogenesis has been largely overlooked.
29-O-(2-methoxyethyl) (MOE)-modified antisense oli-
gonucleotides (ASOs) with a phosphorothioate backbone
that target an hnRNP-A1/A2-dependent splicing silencer,
ISS-N1, in SMN2 intron 7 restore full-length SMN ex-
pression by correcting SMN2 exon 7 splicing (Singh et al.
2006; Hua et al. 2007, 2008, 2010). We recently showed
that an 18mer ASO (ASO10–27, also known as ISIS-
SMNRx) robustly rescues severe SMA mice when de-
livered systemically, whereas much more modest, albeit
significant, rescue is obtained by intracerebroventricular
(ICV) administration to selectively increase SMN levels
in the CNS (Hua et al. 2011). These data clearly demon-
strated that SMN expression in peripheral tissues plays
an important role in murine SMA pathology. The ASO
does not cross an intact adult blood–brain barrier (BBB).
However, the BBB of neonatal mice allows some ASO
molecules to penetrate into the CNS after systemic
administration, resulting in moderate increases in
SMN2 exon 7 inclusion in both the brain and spinal cord
(Hua et al. 2011). This raised the questions of whether
BBB permeability is essential for the long-term rescue
achieved by systemic ASO delivery in neonatal mice
and therefore whether increasing SMN in the CNS is
necessary—although not sufficient—for efficient rescue
of the SMA phenotype. Answering these questions is of
paramount importance for understanding SMA pathogen-
esis in the mouse models and has clinical implications
as well. Currently, ASO10–27 is in phase 3 clinical trials
and is being delivered intrathecally to SMA infants and
children. Whether it will be desirable to deliver this and
other SMA drugs also by systemic routes needs to be
addressed. Answering this important question will help
to optimize treatment modalities.
Here, we address these questions using both mild and
severe SMA mouse models. We took advantage of
ASO10–27 and a complementary decoy oligonucleotide
designed to neutralize ASO10–27 (Rigo et al. 2014). We
combined subcutaneous (SC) treatment of ASO10–27 and
ICV treatment with excess decoy in both the mild and
severe models; the decoy efficiently abrogated the effect
of ASO10–27 in the CNS. To our surprise, increasing
SMN levels in the CNS was not required in either mouse
model for efficient phenotypic rescue. In the severe
model, increasing SMN levels in peripheral tissues ex-
clusively was sufficient for the rescue of motor neurons
and long-term survival, indicating that peripheral defects
play a key role in SMA pathogenesis.
Results
Peripheral SMN restoration completely rescued distal
necrosis in a mild SMA mouse model
Multiple SMA mouse models have been reported. One
mild model (Smn/; SMN22TG/2TG) carries four copies of
an SMN2 transgene in a FVB/N strain background; it
survives normally, but several days after birth, it develops
edema in its tail, which appears short and thick (Hsieh-Li
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et al. 2000). At ;3 wk postnatally, necrosis develops at
the tail tip, gradually spreading to the entire tail until it is
completely lost. Necrosis and subsequent loss of the ear
pinnae also occur after ;1 mo postnatally. We previously
showed that the onset of distal necrosis in this mouse
model can be delayed to 1–2mo by embryonic or neonatal
ICV injection of ASO10–27 (Hua et al. 2010). Here, we
asked whether the necrotic phenotype in this model can
be rescued by systemic ASO treatment.
Newborn pups were administered two SC injections of
ASO10–27 at 40, 80, or 120 mg/kg; one injection was on
postnatal day 0 (P0), and the other was on P2. All doses
tested completely prevented necrosis in both the tail and
ear pinnae of the treated mice throughout their lives.
However, the tails of mice treated with the highest dose
were significantly longer compared with the lower doses,
although still ;1.6 cm shorter than those of untreated
heterozygous mice (Fig. 1A,B). We further tested whether
delayed treatment could also achieve a similar rescue.
Mice were treated with two SC injections of 120 mg/kg
ASO10–27 at 1 or 2 wk of age. Again, distal necrosis was
completely prevented, and the tail length for all mice was
>5 cm long (Fig. 1C). Since edema in the tail appears in the
first postnatal week and tail necrosis starts early during
the fourth week, these data demonstrate that SC ASO
treatment at a relatively late stage can still reverse the
pathological process and robustly restore the normal
growth and maintenance of the tail.
As mentioned above, subcutaneously injected ASO can
cross the immature BBB of neonatal mice and moderately
increase SMN levels in the CNS (Hua et al. 2011). To
address whether the increase in SMN in the CNS is
required for rescue of distal tissue necrosis, we treated
mice after the onset of necrosis, between P22 and P26
(Fig. 1C,D). At this postnatal stage, SC delivery of
ASO10–27 had no effect on SMN2 splicing in the brain
and spinal cord based on analysis by radioactive RT–PCR,
indicating that the BBB is already fully established and
impermeable to the ASO (Fig. 1E,F). Interestingly, the
delayed treatment still rescued the healthy portion of the
tail and prevented ear necrosis (Fig. 1D). These data
demonstrate that increasing the SMN levels in peripheral
tissues is sufficient to rescue the phenotype of mild SMA
mice and also that therapy to prevent necrosis has a broad
temporal window.
Coadministration of decoy with ASO10–27 had no
negative effect on tail growth and maintenance in mild
SMA mice
We used a novel ‘‘decoy’’ approach to further evaluate the
therapeutic importance of the SMN increase in the CNS of
the mild SMA mouse model. The decoy is a synthetic
oligonucleotide harboring the same modifications as the
therapeutic ASO10–27, also 18 nt long, and is exactly
complementary to ASO10–27 in sequence; thus, it is
a ‘‘sense’’ oligonucleotide that can neutralize the effect of
ASO10–27 by sequestering it through Watson-Crick base-
pairing (Rigo et al. 2014). To determine the ICV dose of
decoy required to effectively sequester the systemically
administered therapeutic ASO that reaches the CNS, we
tested two doses, 10 and 20 mg, based on our past
experience with ASO10–27 administered by ICV and SC
routes (Hua et al. 2010, 2011).
We injected the decoy solution ICV at P0–P1; at P0–P2,
we also gave two SC injections of ASO10–27 at 120mg/kg
Figure 1. Systemic delivery of ASO10–27 promotes tail growth
and prevents necrosis in mild SMA mice. (A) Dose-dependent
tail growth and complete prevention of tail necrosis were
achieved by two SC injections of ASO10–27 at 0 mg/kg (SC0,
n = 13), 40 mg/kg (SC40, n = 13), 80 mg/kg (SC80, n = 14), or 120
mg/kg (SC120, n = 18) on P0 and P2, one injection per day.
Untreated heterozygous mice (Het, n = 13) were used as normal
controls. Tail length was measured weekly for up to 3 mo. (B)
Pictures of 3-mo-old mice treated as in A. (C) Prevention of tail
necrosis was achieved by two late SC injections at 120 mg/kg.
Injections were performed on P0 and P2 (P0P2, n = 13), on P7 and
P9 (P7P9, n = 20), on P14 and P16 (P14P16, n = 12), or between
P23 and P31 (P23–31, n = 11) for each mouse. For the P23–P31
group, necrosis was just starting on the tail tip. (D) Mice in the
P23–P31 group at the time of the first injection of ASO10–27
(left) and 5 mo after treatment (right). (E) Analysis of SMN2 exon
7 inclusion in the liver, brain, and spinal cord of P23–P31 mice
by radioactive RT–PCR. Saline treatment was used as a control.
Tissues were collected 5 d after the second injection. (FL) Full-
length transcript; (D7) exon 7-skipped transcript; [Incl (%)] 1003
FL/(FL + D7). (F) Histogram of exon 7 inclusion data from E (n =
3). (*) P < 0.001; (#) P > 0.05.
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per injection. SMN2 exon 7 inclusion levels in the spinal
cord, brain, and liver, analyzed on P7, indicate that 10 mg
of decoy was sufficient to block splicing correction by
sequestering the ASO10–27 molecules that penetrated
the CNS after the double SC dosing (Fig. 2A,B). The decoy
by itself had no toxicity and did not affect SMN2 splicing
(Supplemental Fig. S1). Interestingly, coadministration of
ASO10–27 and the decoy had no effect on tail growth
compared with ASO10–27 treatment alone, and no necrosis
occurred in any mouse treated with both ASO10–27 and
the decoy (Fig. 2C). These data confirm that the distal
necrosis observed in mild SMA mice is mainly or exclu-
sively a peripheral defect.
Coadministration of decoy did not reduce survival
of a severe SMA mouse model
We next used the same decoy approach to address whether
increasing SMN in the CNS is essential to rescue severe
SMA mice. The phenotype of the severe SMA model
(Smn/; SMN22TG/0), generated by crossbreeding themild
SMA mice (Smn/; SMN22TG/2TG) with heterozygous
knockout mice (Smn+/), is similar to that of the SMND7
model, including characteristic NMJ defects, motor neu-
ron loss, and a life span of 1–wk (Riessland et al. 2010). We
set up three experimental groups: Mice in the untreated
group did not receive either ASO10–27 or the decoy but
just saline, the SC-alone group was treated with one SC
injection of ASO10–27 at 120 mg/kg per day from P0 to
P2, and the SC+decoy group was treated as the SC-alone
group, but with additional ICV administration of the
decoy at a total dose of 30 mg (10 mg on P0 plus 20 mg
on P2). We collected the spinal cord, brain, and liver on
P7; extracted total RNA; and analyzed it by radioactive
RT–PCR.
SC administration of ASO10–27 alone promoted strong
SMN2 exon 7 inclusion in the liver and moderate in-
clusion in the CNS; additional ICV delivery of the decoy
strikingly decreased exon 7 inclusion in the CNS but did
so only marginally in the liver (from 72% to 62%) (Fig.
3A,B). In the SC+decoy group, the extent of SMN2 exon 7
inclusion in either the brain or spinal cord was slightly
higher than that in the untreated group, which we
attribute to exacerbation of the splicing defect at the
end stage of the disease in the untreated group, as shown
in our previous study (Sahashi et al. 2012). Consistent
with this interpretation, there was no difference in exon 7
inclusion in the CNS between the SC+decoy and un-
treated groups in both mild SMA mice (Fig. 2A,B) and
healthy heterozygous littermates (Supplemental Fig. S1).
Western blot analysis showed corresponding changes at
the SMN protein level in the liver, brain, and spinal cord
of mice between the SC+decoy and SC-alone groups (Fig.
3C,D). We also performed immunohistochemistry of
brain and spinal cord sections with a polyclonal antibody
that recognizes the phosphorothioate backbone in both
ASO10–27 and the decoy and with a monoclonal anti-
body against SMN. Tissue samples were collected on P7.
Whereas SC dosing alone resulted in increased SMN
staining in the brain and spinal cord, the additional decoy
treatment markedly reduced SMN staining in both tis-
sues (Fig. 4; Supplemental Fig. S2). Furthermore, we
performed immunofluorescence using antibodies against
the motor neuron marker choline acetyltransferase
(ChAT) and against SMN to count gems in spinal cord
a-motor neurons in the ventral horn of lumbar segments
L1–L2. A striking reduction in the number as well as the
size of SMN-positive gems was observed after the addi-
tional ICV decoy treatment compared with SC dosing of
ASO10–27 alone (Fig. 5), again demonstrating the effec-
tiveness of the decoy.
Mice treated with SC dosing alone had a median
survival of 237 d (Fig. 6A); the ;24-fold median survival
increase compared with untreated mice, which survived
;10 d, is consistent with our previous data (Hua et al.
2011). Surprisingly, in spite of its successful abrogation of
the SMN increase in the CNS, the decoy treatment did
not significantly decrease survival compared with SC
dosing alone: The median survival in the SC+decoy group
reached 212 d (Fig. 6A). Remarkably, the majority of the
rescued mice in both groups showed no signs of motor
defects: They could run, climb, and hang from their
forelimbs. We recorded the body weight weekly for up
to 2 mo; the additional decoy treatment had no impact on
weight gain (Fig. 6B). In both groups, the tail length of the
rescued mice ranged from 3 to 5 cm, and most of them
developed late tail necrosis at ;1 yr (data not shown).
Figure 2. Intracerebroventricularly injected decoy oligonucle-
otide neutralized the CNS effect of subcutaneously injected
ASO10–27 but had no negative impact on tail growth and
prevention of necrosis in mild SMA mice. (A) RT–PCR analysis
of SMN2 exon 7 splicing in the spinal cord, brain, and liver of
mice that received two SC injections of ASO10–27 at 120 mg/kg
per injection on P0 and P2, one injection per day, together with
ICV delivery of 0 mg of decoy (decoy-0) or 10 mg of decoy (decoy-
10) on P0 or 20 mg of decoy (decoy-20) on P0 and P2 (10 mg per
day). The control group was treated with saline for both SC and
ICV injections (untreated). Tissues were collected on P7. (B)
Histogram of exon 7 inclusion data from A (n = 3). (*) P < 0.001
versus the untreated group; (#) P > 0.05 versus untreated mice.
(C) Tail growth of decoy-0 (n = 18) and decoy-20 (n = 15) groups
as described in A. Tail length was measured weekly for up to
3 mo; no necrosis occurred in decoy-20 mice throughout their
lives. Heterozygous littermates (Het, n = 13) were used as
normal controls.
Motor neuron cell-nonautonomous rescue of SMA mice
GENES & DEVELOPMENT 291
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
Coadministration of the decoy with ASO10–27 did not
negatively impact motor neuron count and NMJ
integrity
Motor neuron degeneration is a hallmark of SMA pathol-
ogy. Using ChATas amotor neuronmarker, we compared
the number of a-motor neurons in lumbar segments L1–
L2 of severe SMA mice treated with ASO10–27 SC with
or without ICV decoy; there was no significant difference
between these groups, and, in both cases, the motor
neuron number was comparable with that of heterozy-
gous mice (Fig. 6C,D).
Recent studies revealed NMJ defects as a characteristic
feature of SMA pathology and potentially the cause of, or
a contributor to, motor neuron death and muscle atrophy
(Kariya et al. 2008). Muscles are selectively affected, and
one of the most vulnerable muscles in the SMND7mouse
model is the longissimus capitus, which shows ;28%
fully denervated fibers in this slightly milder model at the
end stage (P12–P14) (Ling et al. 2012). We first examined
theNMJ architecture in this muscle using in toto staining
of teased muscle fibers from the severe mouse model.
Motor endplates, presynaptic terminals, and neurofila-
ments were labeled with a-bungarotoxin and antibodies
against synaptophysin and neurofilament-M isoform, re-
spectively. Postsynaptic acetylcholine receptor (AChR)
clusters have been classified into five sequential stages
based on their topological complexity during postnatal
development: plaque-shaped, ring-shaped/perforated, fold/
C-shaped, branched, and pretzel-like (Kummer et al. 2004;
Sahashi et al. 2012). We did not observe fully denervated
fibers in the longissimus capitus in this mouse model
(Fig. 6E), but immature plaque-shaped AChR aggregates
were prevalent in P9 SMA mice compared with hetero-
zygous controls that hadmoremature (branched or pretzel-
like AChR) aggregates, indicating a defect in endplate
maturation (Fig. 6F). We next compared the NMJ AChR
topology of the longissimus capitus between the SC-alone
and SC+decoy groups. Muscle samples were collected
on P21; we observed no significant differences between
the two treatment groups, and both were similar to the
heterozygous controls (Fig. 6G).
Finally, despite the lack of anatomical and behavioral
differences between rescued mice in the SC-alone and
coadministered groups, we attempted to detect subtle
differences in motor function using grip strength and
rotarod tests. There was no difference in forelimb grip
Figure 3. ICV delivery of decoy abrogated the CNS effect of
subcutaneously administered ASO10–27 in severe SMA mice.
(A) RT–PCR analysis of SMN2 exon 7 splicing in the spinal cord,
brain, and liver of mice treated with three SC injections of
ASO10–27 at 120 mg/kg per injection between P0 and P2, one
injection per day, together with ICV injection of saline (SC-
alone) or 30 mg of decoy (SC+decoy) on P0 (10 mg) and P2 (20 mg).
The control group was treated with saline for both SC and ICV
injections (untreated). Tissues were collected on P7. (B) Histo-
gram of exon 7 inclusion data from A (n = 3). (**) P < 0.01 versus
the other two groups; (*) P < 0.01 versus untreated mice; (D) P <
0.05 versus untreated mice. (C) Western blotting analysis of
SMN levels in the spinal cord, brain, and liver of mice as
described in A. Tissues were collected on P7. Tubulin was used
as a loading control. (D) Histogram of SMN levels relative to
tubulin levels from C (n = 3). Data were normalized to the
untreated group. (**) P < 0.05 versus the other two groups; (*) P <
0.01 versus untreated mice; (#) P > 0.05 versus untreated mice.
Figure 4. Immunohistochemical staining of ASO and SMN in
spinal cord cross-sections of severe SMA mice. Mice were
treated with either SC and ICV injections of saline (A–C;
untreated), three SC injections (one injection per day between
P0 and P2) of ASO10–27 alone at 120 mg/kg (D–F; SC-alone), or
both SC injections of ASO10–27 as in the SC-alone group and
ICV injection of 30 mg of decoy oligonucleotide, on P0 (10 mg)
and P2 (20 mg) (G–I; SC+decoy). Tissues were collected on P7
(n = 3 for all groups). A, D, andGwere stained with hematoxylin
and eosin (H&E). B, E, and H were probed with a rabbit poly-
clonal antibody that recognizes the phosphorothioate backbone
of both ASO10–27 and the decoy oligonucleotide. C, F, and
I were probed with a monoclonal human-specific anti-SMN
antibody, SMN-KH. Nuclei were counterstained with DAPI.
Hua et al.
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strength at 2–3 mo (Fig. 6H). The rotarod test likewise
showed no significant difference in performance between
the two groups (Fig. 6H).
Discussion
It has been generally accepted that spinal cord a-motor
neurons are the principal and directly affected cells in
SMA and that motor neuron defects cause global muscle
atrophy, leading to serious consequences, including re-
spiratory failure and premature death in the more severe
forms of SMA. Therefore, increasing SMN in motor
neurons has been presumed to be essential and poten-
tially sufficient for effective SMA therapy. Gavrilina et al.
(2008) reported that a small increase of SMN in neurons
strikingly extended the survival of severe SMA mice
carrying an SMN cDNA transgene driven by a neuron-
specific promoter. However, the mouse prion promoter
used in that study is also active in many nonneuronal cell
types and peripheral tissues (Brown et al. 1990), which
may have contributed to phenotypic rescue. Indeed,
several recent studies using variousmousemodels showed
that restoring SMN expression only in motor neurons or
pan-neuronally resulted in a limited survival increase
(Gogliotti et al. 2012; Lee et al. 2012; Martinez et al.
2012). In accordance with these findings, we recently
demonstrated an essential role of SMN expression in
peripheral tissues for long-term rescue of severe SMAmice
(Hua et al. 2011).
Although accumulating evidence has revealed the
critical importance of cells other than motor neurons in
SMA pathogenesis, it is still a consensus view that
increasing SMN in the CNS, particularly spinal cord
motor neurons, is at least required, if not sufficient, for
SMA therapy. In the present study, we used ASO10–27
and a decoy neutralizer to address whether the CNS is an
essential target for rescuing SMA mice. To our surprise,
we found that restoring SMN expression in the CNS is
not required for rescuing either mild or severe SMAmice.
First, we showed that systemic administration of ASO10–
27 in mild SMA mice efficiently promoted tail growth
and completely prevented the distal necrosis and that
such rescue did not require increasing SMN in the CNS.
Second, we showed that restoring SMN expression in
peripheral tissues alone robustly rescued severe SMA
mice, resulting in a 21-fold increase of life span as well
as improved motor neuron counts and NMJ morphology.
Our data demonstrate that peripheral tissues play a key
role in SMA pathology, including tissue necrosis, motor
neuron loss, motor defects, and premature death in
mouse models.
The mild mouse models do not exactly phenocopy
human type III SMA. The overt phenotype of thesemouse
models is distal tissue necrosis, particularly in the tail
and ear pinnae, due to compromised vascular perfusion
and subsequent thrombosis (Tsai et al. 2006; Narver et al.
2008), which has not been documented in patients with
types II–IV SMA. However, vasculopathy has been occa-
sionally observed in type I patients when their survival
was significantly extended due to improvements in
palliative care (Araujo et al. 2009; Rudnik-Schoneborn
et al. 2010). Similarly, necrosis in the tail, ear pinnae, feet,
legs, anus, etc. is manifested in severe SMA mice when
their survival is extended after treatment with therapeu-
tic drugs (Narver et al. 2008; Hua et al. 2011; Passini et al.
2011; Porensky et al. 2012).
According to our earlier study, the life span of ASO-
rescued mice negatively correlates with the severity of
necrosis (Hua et al. 2011), suggesting that vascular
necrosis may play a role in premature death. The mech-
anism leading to the vascular abnormality is unknown;
our data suggest that the CNS components of the skeletal
muscle motor units as well as the autonomic nervous
system (ANS) are not involved in distal tissue necrosis.
The full rescue of necrosis in mild SMA mice achieved
by peripheral SMN increase appears inconsistent with
our previous study, in whichwe observed delay of necrosis
by embryonic or neonatal ICV injection of ASO10–27 (Hua
et al. 2010). However, in contrast to the CNS administra-
tion, the systemic ASO administration resulted in complete
rescue. The fact that CNS administration resulted in a delay
in tail and ear necrosis is likely due to partial ASO
Figure 5. Gem counts in spinal cord L1–L2 motor neurons of
mice. Mice were treated with either SC and ICV injections of
saline (A–C; untreated, n = 3), three SC injections (one injection
per day between P0 and P2) of ASO10–27 alone at 120 mg/kg
(D–F; SC-alone, n = 3), or both SC injections of ASO10–27 as in
the SC-alone group and ICV injection of 30 mg of decoy oligonu-
cleotide on P0 (10 mg) and P2 (20 mg) (G–I; SC+decoy, n = 3). Tissues
were collected on P7. Immunofluorescence of paraffin-embedded
sections was carried out to detect SMN and ChAT; nuclei were
counterstained with DAPI. Gems per 100 motor neurons (J) and
percentage of motor neurons containing zero, one, two, three, or
four or more gems (K) in the above three groups were calculated.
(*) P < 0.01 versus the other two groups; (D) P < 0.05 versus the
other two groups; (#) P > 0.05 versus untreated mice.
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clearance from the CNS into the blood and subsequent
uptake by peripheral tissues. Indeed, neonatal SC in-
jection with only 10 or 20 mg of ASO10–27 resulted in
a rescue of necrosis similar to that observed with the ICV
delivery route (Supplemental Fig. 3).
The most surprising discovery in the present study is
that long-term survival (21-fold increase) as well as motor
function improvements, rescue of motor neuron counts,
and NMJ maturation in ASO-treated severe SMA mice
did not require SMN levels to increase in the CNS. This
unexpected finding indicates that the basal SMN protein
levels in the CNS are already sufficient for normal mouse
development, provided that a sufficient increase in SMN
levels in peripheral tissues can be achieved. Consistent
with this interpretation, using a conditional knockout
strategy, Park et al. (2010) recently found that 70% of
mice with selective depletion of SMN in motor neurons
survived over a year.
Porensky et al. (2012) reported that ICV injection of
PMO ASO10–29 at a dose of 27, 54, or 81 mg in the
SMND7 model (which has a slightly milder phenotype
than the severe model that we used here) led to a sixfold
to sevenfold survival increase; the investigators proposed
that early and sustained increase of SMN in the CNS is
essential for SMA therapy. However, the strong survival
increase that they reported was less striking than what
we obtained in the more severe model with peripheral
rescue alone. In addition, as stated above, some of the
ASO injected into the CNS is cleared with CSF into the
blood and circulates to peripheral tissues. Porensky et al.
(2012) reported no statistically significant peripheral
effect on SMN2 splicing after ICV injection of the middle
dose; however, this may be attributable to the small
sample size (n = 2), as an approximately twofold increase
in SMN2 full-length mRNA in the liver and heart was
actually observed. Amore recent study using 25mer PMO
(PMO25) confirmed that systemic delivery at high doses
robustly rescues severe SMA mice (Zhou et al. 2013).
Compared with our previous ICV rescue data, the PMO
ASOs appeared to result in stronger rescue (at higher
doses) through ICV delivery (Hua et al. 2011; Passini et al.
2011). However, the differences in animal models, ASO
Figure 6. Increase of SMN in peripheral tissues alone robustly
rescued the phenotype of severe SMA mice. The SC-alone group
was treated with three SC injections of ASO10–27 at 120 mg/kg
at P0–P2, the SC+decoy group was treated as in the SC-alone
group plus ICV delivery of 30 mg decoy at P0–P2, and mice that
received SC and ICV injections of saline were used as controls
(untreated). (A) Survival curves. P < 0.001 for either the SC-alone
(n = 19) or the SC+decoy (n = 27) group versus untreated mice
(n = 18). P = 0.5496 for the SC-alone versus the SC+decoy group.
(B) Body weight curves were similar for the SC-alone and SC
+decoy groups. Untreated heterozygous littermates (Het-Con,
n = 12) were used as positive controls. (C) Immunofluorescence
of spinal cord L1–L2 sections with primary antibody against
ChAT and Alexa fluor 568 secondary antibody. Nuclei were
counterstained with DAPI. Tissues were collected on P7. (D)
Motor neurons in the spinal cord L1–L2 ventral horn labeled
as in C were counted (n = 6). (*) P < 0.01 versus all three groups;
(#) P > 0.05 versus the SC-alone group. (E) NMJ staining of the
longissimus capitus of SMA mice (untreated) and heterozygous
littermates (Het-Con) reveals no denervation of this muscle.
Tissues were collected on P9. Representative pictures are shown.
(Red) Endplates; (blue) synaptic vesicles; (green) neurofilaments.
(F) Quantitation of AChR cluster shapes of the longissimus
capitus (n = 3) NMJs (n > 100) as stained in E. Mature AChR
clusters include branched and pretzel-like clusters. (*) P < 0.05
versus heterozygous controls. (G) Quantitation of AChR cluster
shapes of the longissimus capitus NMJs (n > 100) in P21 mice
(n = 3). (#) P > 0.05 compared with the other two groups. (H) Grip
strength and rotarod tests of rescued SMA mice (n = 10) at 2–3
mo of age. (*) P < 0.05 versus the other two groups; (#) P > 0.05
versus the SC-alone group.
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lengths, treatment timing, and dosage between these
separate studies likely influenced the therapeutic out-
come. Thus, a more systematic study is needed to
rigorously compare ASO chemistries through either ICV
or systemic delivery routes.
Our data reveal that low basal levels of SMN in the
CNS, together with increased SMN in peripheral tissues,
are sufficient to maintain relatively normal NMJ archi-
tecture andmotor neuron function, suggesting a non-cell-
autonomous mechanism of motor neuron degeneration
in SMA. On the other hand, in several studies, including
our own, selective depletion of SMN in motor neurons
induces NMJ defects, and restoration of SMN rescues
them, indicating a cell-autonomous mechanism (Park
et al. 2010; Gogliotti et al. 2012; Lee et al. 2012; Martinez
et al. 2012; Sahashi et al. 2012, 2013). This apparent
discrepancy may be due to the extremely low SMN levels
in motor neurons in these studies. Here we provide direct
evidence demonstrating that cells outside the CNS con-
tribute to the maintenance of motor neurons.
Noncell autonomy is a well-established phenomenon
in several neurodegenerative diseases. For example,
microglia and astrocytes significantly contribute to motor
neuron death in mutant Cu/Zn superoxide dismutase
(SOD1)-induced amyotrophic lateral sclerosis (Ilieva et al.
2009). In the case of SMA, supporting cells, such as
Schwann cells, may be an important contributing factor
in NMJ pathology. Indeed, a recent study revealed a re-
duction of terminal Schwann cells in the Smn2B/mouse
model (Murray et al. 2012). Alternatively, or in addition,
healthy peripheral tissues may supply essential neuro-
trophic factors or prevent the production of toxic factors
that affect motor neuron maintenance. The systemic
milieu affecting neural activities has been well docu-
mented; for example, an increase in circulating chemo-
kines partly contributes to the aging-related decline of
neurogenesis and impaired learning and memory (Villeda
et al. 2011). We and others have shown that circulating
IGF1, a neurotrophic factor produced in the liver, is
reduced in SMA mice and restored upon systemic ASO
therapy (Hua et al. 2011; Murdocca et al. 2012).
Selective restoration of SMN expression in neurons or
muscles does not efficiently improve the survival of
severe SMA mice (Gogliotti et al. 2012; Lee et al. 2012;
Martinez et al. 2012). Here, we further showed that
increasing SMN in the CNS is not required for efficient
rescue of severe SMAmice. It remains to be seen to what
extent the present observations, made in neonate mouse
models, are directly relevant to human SMA. We note
that various SMA therapeutic strategies—some already
in clinical trials—were tested and optimized in similar
mouse models, so developing a detailed understanding of
the similarities and differences in SMA pathophysiology
in human versus mouse models will be crucial.
Materials and methods
Oligonucleotide synthesis
The synthesis and purification of ASO10–27 (59-TCACTTTCA
TAATGCTGG-39) and decoy (59-CCAGCATTATGAAAGTGA-39)
MOE-modified oligonucleotides with phosphorothioate backbone
and all 5-methylcytosines were performed as described (Hua et al.
2010). The oligonucleotides were dissolved in 0.9% saline.
Animals and oligonucleotide treatment
All mouse protocols were in accordance with Cold Spring Harbor
Laboratory’s Institutional Animal Care andUseCommittee guide-
lines. The mild Hung mouse model (Smn/; SMN22TG/2TG) was
the strain FVB.Cg-Tg(SMN2)2HungSMN1tm1Hung/J, founder line
2, purchased from Jackson Laboratory (stock no. 005058). The
severe SMA model (Smn/; SMN22TG/0) was generated as pre-
viously described (Hua et al. 2011). The oligonucleotide solu-
tions were injected subcutaneously into the upper back or
intracerebroventricularly with a 5-mL syringe and 33-gauge
custom removable needle (Hamilton) as described (Hua et al.
2010).
Radioactive RT–PCR and Western blotting
Fresh mouse tissues were rinsed with 0.9% saline and snap-
frozen in liquid N2. Collection of total RNA and protein samples,
RT–PCR with 32P-dCTP, PCR product analysis, Western blot-
ting, and protein quantitation were as described previously (Hua
et al. 2011). The monoclonal antibody against SMN, polyclonal
antibody against b-tubulin, and secondary antibody IRDye
800CW- or 700CW-conjugated goat anti-mouse or anti-rabbit
were purchased from BD Biosciences, GenScript, and LI-COR.
Histology
Spinal cords were fixed with 4% (v/v) formaldehyde in phos-
phate-buffered saline overnight. Oligonucleotide and SMN im-
munohistochemistry was performed as described (Hua et al.
2010). For gem counting in motor neurons and motor neuron
counting in lumbar spinal cord segments L1–L2, paraffin-em-
bedded 6-mm sections were treated with citrate buffer for antigen
retrieval (Sahashi et al. 2012) and incubated with goat anti-ChAT
antibody (Millipore) and/or mouse SMN antibody (BD Biosci-
ence) followed by donkey anti-goat Alexa fluor 568 (Invitrogen)
and/or donkey anti-mouse Alexa fluor 488 secondary antibodies.
For NMJ staining, after perfusing and post-fixing, the long-
issimus capitus was dissected and teased into layers five to 10
fibers thick; NMJ was stained as previously described (Sahashi
et al. 2012). Confocal immunofluorescence imaging was per-
formed with an LSM710 confocal microscope (Carl Zeiss) by
merging Z-stacks of multiple planes into one image.
Motor function tests
Grip strength was measured using a grip strength meter (Colum-
bus Instruments) as previously described (Hua et al. 2011).
Rotarod tests were carried out with a RotaRodIV instrument
(AccuScan); the rotation was set at a constant rate of 5 rpm in one
direction for a maximum of 180 sec. Among 10 trials for each
mouse, the longest time that the mouse stayed on the rod was
recorded.
Statistical analysis
Statistical significance was analyzed by two-tailed Student’s
t-tests. Kaplan-Meier survival curves were prepared with Prism
5 (GraphPad) and analyzed with the Mantel-Cox test. P < 0.05
was considered statistically significant; in all of the figures, data
are presented as mean + SD.
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